Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-16 pm EDT			5-day change	1st Jan Change
10.08 ^USD	-1.51%		-4.45%	+50.00%

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM

Transcript : Novavax, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-19-2025 04

Published on 11/19/2025 at 02:05 pm EST - Modified on 11/19/2025 at 02:35 pm EST

S&P Capital IQ

Presenter Speech
Jiale Song (Analysts)

Welcome to Jefferies London Healthcare Conference 2025. My name is Roger Song, one of the senior analysts cover semicap biotech in the U.S. It is my pleasure to

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Novavax, Inc.

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM
Feb. 26	Health Care Down Amid Mixed Earnings -- Health Care Roundup	DJ
Feb. 26	Novavax raises revenue forecast on boost from vaccine deals, shares soar	RE
Feb. 26	Keros Therapeutics, Inc. Announces Board Changes, Effective March 9, 2026	CI
Feb. 26	Novavax outlook 2026 adjusted total revenue $230 mln - $270 mln	RE
Feb. 26	Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals	RE
Feb. 26	Novavax, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Top Midday Gainers	MT
Feb. 26	Novavax, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Novavax Shares Jump After Swinging to Profit in Q4	MT
Feb. 26	Novavax raises revenue forecast on boost from vaccine deals, shares soar	RE
Feb. 26	Earnings Flash (NVAX) Novavax Posts Q4 Total Revenue $147.1M, vs. FactSet Est of $89.8M	MT
Feb. 26	Earnings Flash (NVAX) Novavax Posts Q4 EPS $0.11, vs. FactSet Est of $0.48 Loss	MT
Jan. 22	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE